| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.15 | 4e-05 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | 0.2 | 5e-05 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | -0.15 | 5e-05 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | -0.18 | 5e-05 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.16 | 5e-05 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | -0.16 | 5e-05 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.19 | 5e-05 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | -0.17 | 5e-05 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.17 | 5e-05 |
| mRNA | bendamustine | CTRPv2 | pan-cancer | AAC | -0.18 | 6e-05 |